Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)

Helen X. Chen; Minkyung Song; Holden T. Maecker; Sacha Gnjatic; David Patton; J. Jack Lee; Stacey J. Adam; Radim Moravec; Xiaole Shirley Liu; Ethan Cerami; James Lindsay; Ming Tang; F. Stephen Hodi; Catherine J. Wu; Ignacio I. Wistuba; Gheath Al-Atrash; Chantale Bernatchez; Sean C. Bendall; Stephen M. Hewitt; Elad Sharon; Howard Streicher; Rebecca A. Enos; Melissa D. Bowman; Valerie M. Tatard-Leitman; Beatriz Sanchez-Espiridion; Srinika Ranasinghe; Mina Pichavant; Diane M.Del Valle; Joyce Yu; Sylvie Janssens; Jenny Peterson-Klaus; Cathy Rowe; Gerold Bongers; Robert R. Jenq; Chia Chi Chang; Jeffrey S. Abrams; Margaret Mooney; James H. Doroshow; Lyndsay N. Harris; Magdalena Thurin

doi:10.1158/1078-0432.CCR-20-3241

Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)

Helen X. Chen, Minkyung Song, Holden T. Maecker, Sacha Gnjatic, David Patton, J. Jack Lee, Stacey J. Adam, Radim Moravec, Xiaole Shirley Liu, Ethan Cerami, James Lindsay, Ming Tang, F. Stephen Hodi, Catherine J. Wu, Ignacio I. Wistuba, Gheath Al-Atrash, Chantale Bernatchez, Sean C. Bendall, Stephen M. Hewitt, Elad SharonHoward Streicher, Rebecca A. Enos, Melissa D. Bowman, Valerie M. Tatard-Leitman, Beatriz Sanchez-Espiridion, Srinika Ranasinghe, Mina Pichavant, Diane M.Del Valle, Joyce Yu, Sylvie Janssens, Jenny Peterson-Klaus, Cathy Rowe, Gerold Bongers, Robert R. Jenq, Chia Chi Chang, Jeffrey S. Abrams, Margaret Mooney, James H. Doroshow, Lyndsay N. Harris, Magdalena Thurin

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Purpose: Immunoprofiling to identify biomarkers and integration with clinical trial outcomes are critical to improving immunotherapy approaches for patients with cancer. However, the translational potential of individual studies is often limited by small sample size of trials and the complexity of immunooncology biomarkers. Variability in assay performance further limits comparison and interpretation of data across studies and laboratories. Experimental Design: To enable a systematic approach to biomarker identification and correlation with clinical outcome across trials, the Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC) Network was established through support of the Cancer MoonshotSM Initiative of the National Cancer Institute (NCI) and the Partnership for Accelerating Cancer Therapies (PACT) with industry partners via the Foundation for the NIH. Results: The CIMAC-CIDCNetwork is composed of four academic centers withmultidisciplinary expertise in cancer immunotherapy that perform validated and harmonized assays for immunoprofiling and conduct correlative analyses. A data coordinating center (CIDC) provides the computational expertise and informatics platforms for the storage, integration, and analysis of biomarker and clinical data. Conclusions: This overview highlights strategies for assay harmonization to enable cross-trial and cross-site data analysis and describes key elements for establishing a network to enhance immuno-oncology biomarker development. These include an operational infrastructure, validation and harmonization of core immunoprofiling assays, platforms for data ingestion and integration, and access to specimens from clinical trials. Published in the same volume are reports of harmonization for core analyses: Wholeexome sequencing, RNA sequencing, cytometry by time of flight, and IHC/immunofluorescence.

Original language	English (US)
Pages (from-to)	5038-5048
Number of pages	11
Journal	Clinical Cancer Research
Volume	27
Issue number	18
DOIs	https://doi.org/10.1158/1078-0432.CCR-20-3241
State	Published - Sep 15 2021

ASJC Scopus subject areas

Oncology
Cancer Research

MD Anderson CCSG core facilities

Biostatistics Resource Group
Microbiome Facility

Access to Document

10.1158/1078-0432.CCR-20-3241

Cite this

Chen, H. X., Song, M., Maecker, H. T., Gnjatic, S., Patton, D., Lee, J. J., Adam, S. J., Moravec, R., Liu, X. S., Cerami, E., Lindsay, J., Tang, M., Hodi, F. S., Wu, C. J., Wistuba, I. I., Al-Atrash, G., Bernatchez, C., Bendall, S. C., Hewitt, S. M., ... Thurin, M. (2021). Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC). Clinical Cancer Research, 27(18), 5038-5048. https://doi.org/10.1158/1078-0432.CCR-20-3241

Chen, HX, Song, M, Maecker, HT, Gnjatic, S, Patton, D, Lee, JJ, Adam, SJ, Moravec, R, Liu, XS, Cerami, E, Lindsay, J, Tang, M, Hodi, FS, Wu, CJ, Wistuba, II , Al-Atrash, G, Bernatchez, C, Bendall, SC, Hewitt, SM, Sharon, E, Streicher, H, Enos, RA, Bowman, MD, Tatard-Leitman, VM, Sanchez-Espiridion, B, Ranasinghe, S, Pichavant, M, Valle, DMD, Yu, J, Janssens, S, Peterson-Klaus, J, Rowe, C, Bongers, G, Jenq, RR , Chang, CC, Abrams, JS, Mooney, M, Doroshow, JH, Harris, LN & Thurin, M 2021, 'Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)', Clinical Cancer Research, vol. 27, no. 18, pp. 5038-5048. https://doi.org/10.1158/1078-0432.CCR-20-3241

@article{36c18b7e536842dea314866bb7b82c06,

title = "Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)",

abstract = "Purpose: Immunoprofiling to identify biomarkers and integration with clinical trial outcomes are critical to improving immunotherapy approaches for patients with cancer. However, the translational potential of individual studies is often limited by small sample size of trials and the complexity of immunooncology biomarkers. Variability in assay performance further limits comparison and interpretation of data across studies and laboratories. Experimental Design: To enable a systematic approach to biomarker identification and correlation with clinical outcome across trials, the Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC) Network was established through support of the Cancer MoonshotSM Initiative of the National Cancer Institute (NCI) and the Partnership for Accelerating Cancer Therapies (PACT) with industry partners via the Foundation for the NIH. Results: The CIMAC-CIDCNetwork is composed of four academic centers withmultidisciplinary expertise in cancer immunotherapy that perform validated and harmonized assays for immunoprofiling and conduct correlative analyses. A data coordinating center (CIDC) provides the computational expertise and informatics platforms for the storage, integration, and analysis of biomarker and clinical data. Conclusions: This overview highlights strategies for assay harmonization to enable cross-trial and cross-site data analysis and describes key elements for establishing a network to enhance immuno-oncology biomarker development. These include an operational infrastructure, validation and harmonization of core immunoprofiling assays, platforms for data ingestion and integration, and access to specimens from clinical trials. Published in the same volume are reports of harmonization for core analyses: Wholeexome sequencing, RNA sequencing, cytometry by time of flight, and IHC/immunofluorescence.",

author = "Chen, {Helen X.} and Minkyung Song and Maecker, {Holden T.} and Sacha Gnjatic and David Patton and Lee, {J. Jack} and Adam, {Stacey J.} and Radim Moravec and Liu, {Xiaole Shirley} and Ethan Cerami and James Lindsay and Ming Tang and Hodi, {F. Stephen} and Wu, {Catherine J.} and Wistuba, {Ignacio I.} and Gheath Al-Atrash and Chantale Bernatchez and Bendall, {Sean C.} and Hewitt, {Stephen M.} and Elad Sharon and Howard Streicher and Enos, {Rebecca A.} and Bowman, {Melissa D.} and Tatard-Leitman, {Valerie M.} and Beatriz Sanchez-Espiridion and Srinika Ranasinghe and Mina Pichavant and Valle, {Diane M.Del} and Joyce Yu and Sylvie Janssens and Jenny Peterson-Klaus and Cathy Rowe and Gerold Bongers and Jenq, {Robert R.} and Chang, {Chia Chi} and Abrams, {Jeffrey S.} and Margaret Mooney and Doroshow, {James H.} and Harris, {Lyndsay N.} and Magdalena Thurin",

note = "Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",

year = "2021",

month = sep,

day = "15",

doi = "10.1158/1078-0432.CCR-20-3241",

language = "English (US)",

volume = "27",

pages = "5038--5048",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "18",

}

TY - JOUR

T1 - Network for Biomarker Immunoprofiling for Cancer Immunotherapy

T2 - Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)

AU - Chen, Helen X.

AU - Song, Minkyung

AU - Maecker, Holden T.

AU - Gnjatic, Sacha

AU - Patton, David

AU - Lee, J. Jack

AU - Adam, Stacey J.

AU - Moravec, Radim

AU - Liu, Xiaole Shirley

AU - Cerami, Ethan

AU - Lindsay, James

AU - Tang, Ming

AU - Hodi, F. Stephen

AU - Wu, Catherine J.

AU - Wistuba, Ignacio I.

AU - Al-Atrash, Gheath

AU - Bernatchez, Chantale

AU - Bendall, Sean C.

AU - Hewitt, Stephen M.

AU - Sharon, Elad

AU - Streicher, Howard

AU - Enos, Rebecca A.

AU - Bowman, Melissa D.

AU - Tatard-Leitman, Valerie M.

AU - Sanchez-Espiridion, Beatriz

AU - Ranasinghe, Srinika

AU - Pichavant, Mina

AU - Valle, Diane M.Del

AU - Yu, Joyce

AU - Janssens, Sylvie

AU - Peterson-Klaus, Jenny

AU - Rowe, Cathy

AU - Bongers, Gerold

AU - Jenq, Robert R.

AU - Chang, Chia Chi

AU - Abrams, Jeffrey S.

AU - Mooney, Margaret

AU - Doroshow, James H.

AU - Harris, Lyndsay N.

AU - Thurin, Magdalena

PY - 2021/9/15

Y1 - 2021/9/15

N2 - Purpose: Immunoprofiling to identify biomarkers and integration with clinical trial outcomes are critical to improving immunotherapy approaches for patients with cancer. However, the translational potential of individual studies is often limited by small sample size of trials and the complexity of immunooncology biomarkers. Variability in assay performance further limits comparison and interpretation of data across studies and laboratories. Experimental Design: To enable a systematic approach to biomarker identification and correlation with clinical outcome across trials, the Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC) Network was established through support of the Cancer MoonshotSM Initiative of the National Cancer Institute (NCI) and the Partnership for Accelerating Cancer Therapies (PACT) with industry partners via the Foundation for the NIH. Results: The CIMAC-CIDCNetwork is composed of four academic centers withmultidisciplinary expertise in cancer immunotherapy that perform validated and harmonized assays for immunoprofiling and conduct correlative analyses. A data coordinating center (CIDC) provides the computational expertise and informatics platforms for the storage, integration, and analysis of biomarker and clinical data. Conclusions: This overview highlights strategies for assay harmonization to enable cross-trial and cross-site data analysis and describes key elements for establishing a network to enhance immuno-oncology biomarker development. These include an operational infrastructure, validation and harmonization of core immunoprofiling assays, platforms for data ingestion and integration, and access to specimens from clinical trials. Published in the same volume are reports of harmonization for core analyses: Wholeexome sequencing, RNA sequencing, cytometry by time of flight, and IHC/immunofluorescence.

AB - Purpose: Immunoprofiling to identify biomarkers and integration with clinical trial outcomes are critical to improving immunotherapy approaches for patients with cancer. However, the translational potential of individual studies is often limited by small sample size of trials and the complexity of immunooncology biomarkers. Variability in assay performance further limits comparison and interpretation of data across studies and laboratories. Experimental Design: To enable a systematic approach to biomarker identification and correlation with clinical outcome across trials, the Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC) Network was established through support of the Cancer MoonshotSM Initiative of the National Cancer Institute (NCI) and the Partnership for Accelerating Cancer Therapies (PACT) with industry partners via the Foundation for the NIH. Results: The CIMAC-CIDCNetwork is composed of four academic centers withmultidisciplinary expertise in cancer immunotherapy that perform validated and harmonized assays for immunoprofiling and conduct correlative analyses. A data coordinating center (CIDC) provides the computational expertise and informatics platforms for the storage, integration, and analysis of biomarker and clinical data. Conclusions: This overview highlights strategies for assay harmonization to enable cross-trial and cross-site data analysis and describes key elements for establishing a network to enhance immuno-oncology biomarker development. These include an operational infrastructure, validation and harmonization of core immunoprofiling assays, platforms for data ingestion and integration, and access to specimens from clinical trials. Published in the same volume are reports of harmonization for core analyses: Wholeexome sequencing, RNA sequencing, cytometry by time of flight, and IHC/immunofluorescence.

UR - http://www.scopus.com/inward/record.url?scp=85104631646&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85104631646&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-20-3241

DO - 10.1158/1078-0432.CCR-20-3241

M3 - Article

C2 - 33419780

AN - SCOPUS:85104631646

SN - 1078-0432

VL - 27

SP - 5038

EP - 5048

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 18

ER -

Network for Biomarker Immunoprofiling for Cancer Immunotherapy: Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons (CIMAC-CIDC)

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this